Enhertu® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival as First-Line Treatment of Patients with HER2 Mutant Advanced Non-Small Cell Lung Can

Statistically significant PFS improvement in Phase 3 trial for first-line HER2-mutant NSCLC.